Trace Minerals Research (TMR), a leading provider of trace mineral–based supplements for over 40 years, announces that it has received results of a six-month clinical trial on ConcenTrace®, its flagship ionic trace mineral supplement that is harvested from the Great Salt Lake in Utah and contains over 72 naturally occurring trace minerals. The double-blind, placebo-controlled randomized study was conducted by doctors Himanshu Bansal, Diwaker Agarwal, R. N. Srivatsava and Anupama Bansal using 100 participants with moderate osteoarthritis of the knee and is titled “Natural Mineral Supplementation Provides Chondro-Protection and Hence Improvement in Moderate Osteoarthritis of Knee.”
“This is a very important clinical trial because it shows the efficacy of ConcenTrace for bone and joint health,” said Matt Kilts, managing partner of TMR. “We know that minerals and trace minerals are so important to the body because they have so many essential functions. Now we have the research that proves they can support bone and joint health.”
Participants were given 40 drops of ConcenTrace or placebo daily for 24 weeks. The study states that “efficacy was objectively confirmed by evaluating changes in the thickness of articular cartilage, joint space width and synovial fluid composition.” Results at 24 weeks state that “ultrasonography and synovial fluid examination revealed improvement in cartilage structure.”
The study also employed the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and a six-minute pain free walking distance (6 MWD) as methods to determine the effectiveness of ConcenTrace. The WOMAC is a widely used measure of a patient’s subjective assessment of pain, joint mobility and physical disability and a score is given for each dimension. After 24 weeks, the study shows that the average WOMAC score from the participants reduced from 16.2 to 7.1 and the average 6 MWD distance increased from 46 feet to 122 feet.